XERS
Xeris Biopharma Holdings, Inc.7.10
+0.05+0.71%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.18BP/E (TTM)
-Basic EPS (TTM)
-0.10Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
10-Q
Q2 FY2025 results
Xeris Biopharma swung to an operating profit of $4.5M in Q2 FY2025 ended June 30, 2025, up from a $8.2M loss a year earlier, while total revenue climbed 48.8% y/y to $71.5M on Recorlev's 135.7% surge to $31.4M from prescription growth, despite Keveyis dipping 12.5% to $11.5M. Gross margin held at 83.4%, but net loss narrowed to $1.9M from $15.0M y/y, with the gap to operating income tied to $7.4M interest expense. Cash dipped to $59.3M from $71.6M year-end, yet free cash flow improved to $(10.1M) from $(31.2M) (derived), backed by $218.6M in long-term debt including $33.6M convertible notes due 2028 at 8.0%. Recorlev drives momentum. Supply disruptions remain a key risk.
8-K
Record Q2 revenue, raised guidance
Xeris Biopharma reported record Q2 2025 revenue of $71.5 million, up 49% year-over-year, fueled by Recorlev's 136% surge to $31.4 million from higher patient numbers, while Gvoke rose 17% to $23.5 million on prescription growth and pricing gains; Keveyis dipped 13% to $11.5 million due to lower shipments. The company raised full-year 2025 revenue guidance to $280-$290 million, signaling strong demand momentum. Net loss narrowed 87% to $1.9 million. Growth accelerates.
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
KROS
Keros Therapeutics, Inc.
21.53+0.30
KRYS
Krystal Biotech, Inc.
238.55-4.43
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
TBPH
Theravance Biopharma, Inc.
17.53-0.24
XBIT
XBiotech Inc.
2.45-0.08
XENE
Xenon Pharmaceuticals Inc.
43.00-0.60
XNCR
Xencor, Inc.
16.55-0.24
XTLB
XTL Biopharmaceuticals Ltd.
0.78-0.03